Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William D Figg

Showing results (81-90 of 639) with videos related to

Pageof 64
Sort By:
Journal of Hematology & Oncology|July 4, 2012
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failuresXuan Huang, Cindy H Chau, William D Figg
Therapeutics and Clinical Risk Management|March 25, 2008
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategyCharity D Scripture, William D Figg, Alex Sparreboom
BJU International|October 10, 2007
Secondary hormonal therapy for prostate cancer: what lies on the horizon?Nima Sharifi, William L Dahut, William D Figg
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
The role of drug-metabolising enzymes in clinical responses to chemotherapyCharity D Scripture, William D Figg, Alex Sparreboom
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
The genetics of castration-resistant prostate cancer: what can the germline tell us?Nima Sharifi, William L Dahut, William D Figg
Cancer Biology & Therapy|May 6, 2017
Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effectsLouis Rodgers, Cody J Peer, William D Figg
The Lancet. Oncology|October 4, 2005
Modulation of cytochrome P450 activity: implications for cancer therapyCharity D Scripture, Alex Sparreboom, William D Figg
Anticancer Research|July 4, 2012
Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancerShawn Spencer, Bernard L Marini, William D Figg
Cancer Biology & Therapy|June 29, 2010
Genetic variant associated with aggressive not indolent prostate cancerC Tyler Kirkland, Douglas K Price, William D Figg
Cancer Biology & Therapy|November 20, 2010
Prostate cancer genomic signature offers prognostic valueSarah M Troutman, Douglas K Price, William D Figg
Pageof 64

Showing results (81-90 of 639) with videos related to

Sort By:
Pageof 64
Journal of Hematology & Oncology|July 4, 2012
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failuresXuan Huang, Cindy H Chau, William D Figg
Therapeutics and Clinical Risk Management|March 25, 2008
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategyCharity D Scripture, William D Figg, Alex Sparreboom
BJU International|October 10, 2007
Secondary hormonal therapy for prostate cancer: what lies on the horizon?Nima Sharifi, William L Dahut, William D Figg
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
The role of drug-metabolising enzymes in clinical responses to chemotherapyCharity D Scripture, William D Figg, Alex Sparreboom
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
The genetics of castration-resistant prostate cancer: what can the germline tell us?Nima Sharifi, William L Dahut, William D Figg
Cancer Biology & Therapy|May 6, 2017
Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effectsLouis Rodgers, Cody J Peer, William D Figg
The Lancet. Oncology|October 4, 2005
Modulation of cytochrome P450 activity: implications for cancer therapyCharity D Scripture, Alex Sparreboom, William D Figg
Anticancer Research|July 4, 2012
Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancerShawn Spencer, Bernard L Marini, William D Figg
Cancer Biology & Therapy|June 29, 2010
Genetic variant associated with aggressive not indolent prostate cancerC Tyler Kirkland, Douglas K Price, William D Figg
Cancer Biology & Therapy|November 20, 2010
Prostate cancer genomic signature offers prognostic valueSarah M Troutman, Douglas K Price, William D Figg
Pageof 64